A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

Clinical trial NCT05658562 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05658562
Sponsor: Tanabe Pharma Corporation
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma

Start date: 2023-01-30
Primary completion: 2028-08-01
Enrollment: 46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.